Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
41 hedge funds and large institutions have $151M invested in Carisma Therapeutics in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
16% more capital invested
Capital invested by funds: $130M → $151M (+$21.1M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
2% less funds holding
Funds holding: 42 → 41 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$7.6M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$6.84M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$2.69M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.33M |
| 5 |
BC
Broadfin Capital
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$659K |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$365K |
| 3 |
JP Morgan Chase
New York
|
-$327K |
| 4 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$127K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$111K |
CARM Hedge Fund Activity: Q4 2014 in Review
41 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2014, worth a combined $151M — up 16% from $130M a quarter earlier.
Fund positioning in CARM was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 15 added to existing stakes and 10 trimmed.
The largest buyer was Sabby Management, adding an estimated $7.6M. The largest seller was Fidelity Investments, cutting an estimated $659K.
- 41 institutional investors held Carisma Therapeutics (CARM) as of Q4 2014, down from 42 in Q3 2014.
- Funds reported $151M of Carisma Therapeutics stock for Q4 2014, up 16% quarter-over-quarter.
- 5 funds opened new Carisma Therapeutics positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Carisma Therapeutics buyer in Q4 2014 was Sabby Management, an estimated $7.6M added.
- The largest Carisma Therapeutics seller in Q4 2014 was Fidelity Investments, an estimated $659K sold.
Based on aggregated 13F filings for Q4 2014.